ABL Bio is one of the world's leading biotech research companies focusing on the development of therapeutic drugs for immuno-oncology & neurodegenerative diseases.
Our vision is to become the world’s leading biotechnology company with innovative platforms and pipelines.
Bispecific antibody platform.
Our core values are life-improvement, collaboration, innovation and novel therapy.
ABL Bio Has Various Platform Technologies To Treat Intractable Diseases.More
ABL Bio is the first biotech company in Korea with a bispecific antibody platform that is undergoing clinical trial.
The Grabody B platform targets insulin-like growth factor 1 receptor (IGF1R) to function as a BBB shuttle
Minimize the systemic toxicity associated with 4-1BB based immunotherapy, increase low reponse rates and overcome the resistance observed with traditional PD-(L)1 therapy
Challenging the development of rare blood cancer treatments with ADC drug candidates that have better in vivo pharmacokinetic parameters
History of ABL Bio
First dosed in Phase 1 clinical trial of ABL301
Article about ABL301 published in Cell Reports Methods
Article about ABL501 published in Molecular Therapy
ABL111 received Orphan-Drug Designation
Signs licensing agreement with Sanofi
re-certified as Korea Innovative Pharmaceutical Company
ABL501 Phase 1 clinical trial IND approved by MFDS
Review paper on bispecific antibody-based immunotherapy published in Vaccines
First patient dosed in Phase 1 clinical trial of ABL111
First patient dosed in Phase 1 clinical trial of ABL503
ABL111 phase 1 clinical trial IND approved by U.S. FDA
ABL001 Phase 2 clinical trial IND approved by MFDS
ABL503 Phase 1 clinical trial IND approved by U.S. FDA
ABL's 4-1BB bispecific antibody introduced in 'Science Advances'
ABL001 research published in International Journal of Molecular Sciences